Evaluation of Patient Characteristics and Treatment Approaches to Patients With Bipolar Disorder in Turkey

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00660712
First received: April 15, 2008
Last updated: May 22, 2009
Last verified: May 2009
  Purpose

A registry study to identify the patient-diagnosis-treatment characteristic profile of patients with bipolar disorder in Turkey.


Condition
Bipolar Disorder

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Evaluation of Patient Characteristics and Treatment Approaches to Patients With Bipolar Disorder in Turkey

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Identification of the patient-diagnosis-treatment characteristic profile of patients with bipolar disorder in Turkey. [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Evaluation of the time period that elapsed since the diagnosis of bipolar disorder [ Designated as safety issue: No ]
  • Evaluation of co-morbid psychiatric diseases [ Designated as safety issue: No ]
  • Identification of treatment modalities selected according to the disease phase [ Designated as safety issue: No ]
  • Identification of the number of first degree relatives diagnosed with bipolar disorder [ Designated as safety issue: No ]
  • Evaluation of the relationship between patient and disease characteristics [ Designated as safety issue: No ]

Enrollment: 1018
Study Start Date: March 2008
Study Completion Date: March 2009
Groups/Cohorts
1
Patients with bipolar disorder

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Speciality care outpatient clinic (Psychiatry outpatient clinic)

Criteria

Inclusion Criteria:

  • Patients previously or currently diagnosed with bipolar disorder
  • Patients (or any of their relatives) who give a written informed consent.

Exclusion Criteria:

  • Patients who were previously included in this study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00660712

Locations
Turkey
Research Site
Adana, Turkey
Research Site
Afyon, Turkey
Research Site
Ankara, Turkey
Research Site
Antalya, Turkey
Research Site
Aydin, Turkey
Research Site
Batman, Turkey
Research Site
Denizli, Turkey
Research Site
Erzincan, Turkey
Research Site
Eskisehir, Turkey
Research Site
Istanbul, Turkey
Research Site
Izmir, Turkey
Research Site
Konya, Turkey
Research Site
Malatya, Turkey
Research Site
Mardin, Turkey
Research Site
Mersin, Turkey
Research Site
Rize, Turkey
Research Site
Samsun, Turkey
Research Site
Sivas, Turkey
Research Site
Trabzon, Turkey
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Mustafa Bilici, MD, Assoc. Prof Erenkoy State Hospital for Psychiatric Diseases, Istanbul, Turkey
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00660712     History of Changes
Other Study ID Numbers: NIS-NTR-DUM-2007/1
Study First Received: April 15, 2008
Last Updated: May 22, 2009
Health Authority: Turkey: Ministry of Health

Keywords provided by AstraZeneca:
Bipolar disorder
patient characteristics
treatment characteristics

Additional relevant MeSH terms:
Bipolar Disorder
Affective Disorders, Psychotic
Mood Disorders
Mental Disorders

ClinicalTrials.gov processed this record on August 01, 2014